Articles tagged with: Dacogen
Headline, News »
One myelodysplastic syndromes (MDS) patient has been reported to have fluid build up, known as effusion, in her lungs and in the area surrounding her heart after taking Dacogen (decitabine). It is the first reported case of effusion induced by the drug.
The sixty year old patient received Dacogen (20 mg/m2 per day) for five days by intravenous injection. Following the therapy, the patient reported a skin rash, slow marrow recovery, and fatigue. She was admitted to the hospital one month post treatment due to neutropenic fever, a…
News »
FDA Considers Alternative Dosing Regimen for Dacogen – A supplemental new drug application for an alternative dosing regimen for Dacogen (decitabine) has been accepted by the United States Food and Drug Administration (FDA). The proposed five day regimen consists of a single daily dose of Dacogen with reduced infusion time, and is likely to be more convenient for patients. The current dosing schedule requires three hours of continuous intravenous administration of Dacogen every eight hours for three days. Dacogen has been approved by the FDA as a treatment for myelodysplastic syndromes. For more information, please see the Eisai press release.
Best of Washington Party – Washingtonian Magazine will hold its annual Best of Washington summer party on Wednesday, July 15 at the National Building Museum in Washington, DC. The event begins at 7 p.m. and ends at 10 p.m. The party features unlimited cocktails and cuisine from over 50 restaurant winners of the magazine’s Best of Washington contests. A portion of the proceeds will be donated to the Leukemia & Lymphoma Society (LLS). Presidential tickets are available at a discount to LLS supporters: use the code LLS1 at the Best of Washington checkout. For more information, please see the Best of Washington 2009 Web site.
Leukemia Cup Regatta – “Sail for the Cures” with the Leukemia & Lymphoma Society (LLS). Upcoming events are scheduled for: July 10 to 12 in Deltaville, VA; July 17 in Beachwood, NJ; and July 16 to 19 in Rocky River, OH. Sailors compete for the Leukemia Cup in honor of a community member with blood cancer with an opportunity to win prizes for raising money to support LLS, including a Fantasy Sail Weekend with world-class sailor and National Regatta Chairman Gary Jobson. For more information, visit the LLS Leukemia Cup Regatta Web site.
News »
The 45th meeting of the American Society for Clinical Oncology (ASCO) provided a forum for myelodysplastic syndromes (MDS) research from the M.D. Anderson Cancer Center in Houston. At the meeting, researchers presented a study that investigated the use of hypomethylating agents Vidaza (azacitidine) and Dacogen (decitabine) for patients with decreased kidney function and concluded that both agents are effective in this patient group.
Vidaza and Dacogen are hypomethylating, or demethylating, agents that allow DNA sequences to function normally. They remove methyl groups that are bound to…
News »
Israeli researchers presented the effectiveness of hypomethylating agents Vidaza (azacitidine) and Dacogen (decitabine) on improving overall survival of myelodysplastic syndromes (MDS) patients. This information was presented at the European Hematology Association (EHA) 14th Congress in Berlin.
Methyl groups that are bound to DNA sequences cause problems by preventing the regulation of cellular growth and causing uncontrollable cell division. Hypomethylating or demethylating agents, like Vidaza or Dacogen, allow the DNA sequences to function normally by removing these problematic methyl groups.
Researchers found four relevant randomized controlled trials,…
News »
On May 29 at the 45th meeting of the American Society for Clinical Oncology (ASCO), researchers from the M.D. Anderson Cancer Center in Houston reported their review of randomized Phase 2 and Phase 3 trials comparing different dosing schedules of Dacogen (decitabine) in myelodysplastic syndromes (MDS) patients. Researchers found that increased numbers of treatment cycles are beneficial for MDS patients.
The Phase 3 trial participants (D-0007 and EORTC-06011) were given 15 mg/m2 intravenously over three hours every eight hours for three days every six weeks with supportive care.…